The Boardroom Series: Interview with Orphazyme's CMO Carlos Camozzi Full Interview

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights click here. By clicking the "Download button" you agree to the terms of our Privacy Policy.

Dr Carlos Camozzi is the new Chief Medical Officer at the Biotech Company Orphazyme, located in Denmark. Carlos has over 25 years in clinical research and development roles in pharma and biotech companies, including leading clinical operations in the rare disease area. Before joining Orphazyme, Dr Camozzi was the VP CMO of uniQure (ex AMT) in Netherlands, and prior to that, he was Medical Director and Head of Medical Affairs with Orphan Europe.

 The landscape for the Pharma industry has changed, both from a scientific and regulatory standpoint. Business models must change in order to stay relevant and deliver the best results for patients. In this Interview Carlos Camozzi argues that a future based on finding the next blockbuster will be difficult and that real advances can be made by shifting focus onto diagnostics and treatments for rare diseases.